227 related articles for article (PubMed ID: 30466339)
1. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
[No Abstract] [Full Text] [Related]
2. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
3. Minimal Residual Disease in Acute Myeloid Leukemia.
Gomez-Arteaga A; Guzman ML
Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
[TBL] [Abstract][Full Text] [Related]
4. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Xu J; Jorgensen JL; Wang SA
Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
Brooimans RA; van der Velden VHJ; Boeckx N; Slomp J; Preijers F; Te Marvelde JG; Van NM; Heijs A; Huys E; van der Holt B; de Greef GE; Kelder A; Schuurhuis GJ
Leuk Res; 2019 Jan; 76():39-47. PubMed ID: 30553189
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges.
Gaipa G; Buracchi C; Biondi A
Expert Rev Mol Diagn; 2018 Sep; 18(9):775-787. PubMed ID: 30047795
[TBL] [Abstract][Full Text] [Related]
7. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
8. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
9. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
11. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
12. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
Roug AS; Ommen HB
Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
[TBL] [Abstract][Full Text] [Related]
13. Effect of processing time on analysis of rare event in minimal residual disease study.
Rai S; Bhardwaj U; Singh S; Misra A
Indian J Pathol Microbiol; 2017; 60(3):449-451. PubMed ID: 28937402
[No Abstract] [Full Text] [Related]
14. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
15. The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia].
Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362
[TBL] [Abstract][Full Text] [Related]
18. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
19. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]